Drug intelligence / Profile preview

GLY-201

Development stage: Preclinical
Lead developer: Glycan Therapeutics
Modality: Microbiome-Derived Products → Microbiome Therapeutics, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules

Overview

GLY-201 is a preclinical-stage oligosaccharide therapeutic developed by Glycan Therapeutics for the treatment of acute liver injury (ALI) and drug-induced acute liver failure (DIALF). It functions by targeting High Mobility Group Box 1 (HMGB1), a nuclear protein that, when released into the extracellular space during tissue injury, acts as a potent pro-inflammatory mediator. GLY-201 specifically inhibits HMGB1-mediated neutrophil recruitment, thereby mitigating sterile inflammation and preventing further hepatic damage.

Targets

HMGB1 (High mobility group protein B1)

Beyond the preview

Go deeper on GLY-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GLY-201.

Explore the full profile